Twist Bioscience Corp vs Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 — how do they compare? Twist Bioscience Corp trades at $152.84 (market cap $10.08B), while Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 trades at $45.28 (market cap $311.72M). The key difference: Twist Bioscience Corp is far larger — about 32.3× Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037's market cap, and Twist Bioscience Corp is trading nearer its 52-week high, Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Twist Bioscience Corp for 27 Days and Ubs Ag Etracs Crude Oil Shares Covered Call ETN Exp 24th Apr 2037 for 48 Days on average.
| TWST | USOI | |
|---|---|---|
Market Cap | $10.08B | $311.72M |
Volume | 4,229,037 | 75,888 |
Sector | Health | Income / Options Overlay |
52-Week High | $205.00 | $61.17 |
52-Week Low | $25.45 | $42.27 |
Typical Hold Time | 27 Days | 48 Days |
Enterprise Value | $10.01B | — |
Signals from Pluang's Aura AI — not financial advice
TWST trades at $155.65, down 6.78% today, reflecting a bearish technical signal and recent earnings misses. Revenue growth is strong, rising to $376.57M in 2025, but profitability remains elusive with a net income margin of -31.66%. The company's partnership with Lilly TuneLab for AI-driven drug discovery has generated positive news flow, yet cash flow remains negative, and the stock trades at elevated valuation multiples like P/S of 22.01.
The outlook is mixed: strong analyst buy-side consensus (73% Buy) and strategic AI partnerships offer growth potential, but persistent losses, high cash burn, and bearish technicals pose significant risks. Investors face a trade-off between long-term innovation prospects and near-term financial instability.
USOI trades at $44.61, down 0.82% today, with a bearish technical signal driven by moving averages. Support levels are at $44 and $43, while resistance sits at $45 and $46. Financial ratios like P/E and P/S are unavailable in the data, limiting fundamental clarity. Recent portfolio commentary from Seeking Alpha on September 3, 2026, highlighted strategic cash-raising moves, though direct company news is sparse.
The outlook is cautious due to weak technical momentum and absent fundamental metrics. Risks include market volatility and lack of earnings visibility. Investment opportunity hinges on a rebound above resistance, but current sentiment and technicals suggest near-term pressure for stockholders.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →USOI is an Exchange-Traded Note (ETN) issued by UBS that provides exposure to a covered call strategy on the United States Oil Fund (USO). It aims to generate high monthly income by capturing option premiums from the hypothetical sale of out-of-the-money call options on oil shares, offering a way to profit from crude oil's volatility even in a flat or range-bound market.
Read more on USOI →